Galileo Genomics Purchases Illumina, Inc. (ILMN) BeadStation Platforms To Fine Map Candidate Regions For At Least Five Disease Gene Discovery Programs
10/19/2005 5:10:51 PM
Illumina, Inc. (NASDAQ:ILMN) and Galileo Genomics Inc. today announced that they have signed a collaborative agreement with a value exceeding $1.5 million. Under the terms of the agreement, Galileo has purchased two Illumina BeadStation 500GX genotyping systems for use in fine mapping candidate regions in a minimum of five disease gene discovery programs. The resulting information will be used to produce GeneMaps, comprised of multiple interacting genes unequivocally associated with disease, which will be used for the development of innovative therapeutics, diagnostics and pharmacogenomics services. Illumina is also licensing the diagnostic rights to Galileo's osteoarthritis gene discovery program.